Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565186 · ClinicalTrials.gov registry record · Phase 3
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,171
- Enrollment target
NCT02565186: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02565186 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,171 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (181% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02565186, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,171 participants
- Enrollment target
Study Summary
This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects with migraine. The study is designed to evaluate the safety and tolerability of long-term intermittent use of lasmiditan 100 mg and of lasmiditan 200 mg, as the first dose and as a second dose, for the acute treatment of migraine. Long term efficacy will also be evaluated.
Primary Outcome
An AE with an onset on or within 48 hours after a dose of study drug, or an event that worsened in intensity within 48 hours of a dose of study drug was considered a treatment-emergent adverse event (TEAE). A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module.
Interventions
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,171 participants |
| Start Date | 2015-10-07 |
| Est. Completion | 2019-08-20 |
| Phase | Phase 3 |
What the finished NCT02565186 record still lists
NCT02565186 is an interventional study that assigns participants to a tested intervention. Its 2,171 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (181% higher).
The record links to 0 conditions, and to 1 intervention - of which Lasmiditan is the first listed.
NCT02565186 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02565186 about?
NCT02565186 is a clinical study titled "An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine". This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects with migraine. The study is designed to evaluate the safety and tolerabi...
What is the current status of trial NCT02565186?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,171 participants. The study started on 2015-10-07. Estimated completion is 2019-08-20.
What interventions are being tested in trial NCT02565186?
The interventions under investigation include: Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT02565186?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02565186's enrollment target sits among peer trials
2,171 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05742178 · 2,160 participants · NA
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
- NCT05917652 · 2,183 participants
The Actuate-CBC Study
- NCT06783335 · 2,150 participants
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI